Human

Cytokine/Chemokine	Clone(s)	Target Cells	Stimulation	Stimulation period	Protein transport blocker	Surface marker
IL-1α	364-3B3-14	PBMCs	LPS (100 ng/ml)	4-6 hours	monensin or brefeldin A	CD14*
IL-1β	JK1B-1	PBMCs	LPS (100 ng/ml)	4-6 hours	monensin or brefeldin A	CD14*
IL-2	MQ1-17H12	PBMCs	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD3
IL-3	BVD3-1F9	Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (5 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3-4 days	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD4*
IL-4	MP4-25D2 or 8D4-8	PBMCs	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD4*
IL-5	JES1-39D10	Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (5 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3-4 days	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD4*
IL-6	MQ2-13A5	PBMCs	LPS (100 ng/ml)	4-6 hours	monensin or brefeldin A	CD14*
IL-8	JK8-1	PBMCs	LPS (100 ng/ml)	4-6 hours	monensin or brefeldin A	CD14*
IL-9	MH9A4	Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (5 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3-4 days	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD4*
IL-10	JES3-9D7 or JES3-19F1	PBMCs	LPS (100 ng/ml)	18-24 hours	monensin or brefeldin A	CD14*
IL-12 p40	C11.5	PBMCs	IFN-γ (100 ng/ml) prime for 2 hours, then add LPS (1 μg/ml)	18-24 hours	monensin or brefeldin A	CD14*
IL-13	JES10-5A2	Purified CD4+ T cells stimulated with immobilized anti-CD3 (10 μg/ml) + soluble anti-CD28 (5 μg/ml) + IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 2 days, wash and then culture in IL-2 + IL-4 for 3-4 days	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD4*
IL-17A	BL168	PBMCs	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD4*
IL-21	3A3-N2 or 4BG1	PBMCS	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD4*
IL-22	BG/IL22	PBMCs	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD4*
GM-CSF	BVD2-21C11	PBMCs stimulated with soluble anti-CD3 (UCHT1, 1 μg/ml) + soluble anti-CD28 (5 μg/ml) for 2 days, wash and then culture in IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 3-4 days	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD3
IFN-γ	4S.B3 or B27	PBMCs	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD3
MCP-1	5D3-F7 or 2H5	PBMCs	LPS (100 ng/ml)	18-24 hours	monensin or brefeldin A	CD14*
TNF-α	MAB11	PBMCs	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD3
TNF-β	359-81-11	PBMCs stimulated with soluble anti-CD3 (UCHT1, 1 μg/ml) + soluble anti-CD28 (5 μg/ml) for 2 days, wash and then culture in IL-2 (20 ng/ml) + IL-4 (50 ng/ml) for 3-4 days	PMA (50 ng/ml) plus ionomycin (1 μg/ml)	4-6 hours	monensin or brefeldin A	CD3